Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics (NKTR) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies for autoimmune disorders and chronic inflammatory diseases. This dedicated news hub provides investors and researchers with timely updates on the company's scientific advancements and corporate developments.
Access authoritative information on NKTR's pipeline progress, including updates on rezpegaldesleukin (Treg stimulator) and NKTR-255 (IL-15 agonist). Our curated collection features press releases about clinical trial milestones, regulatory submissions, strategic partnerships, and financial disclosures.
Key content categories include therapy development breakthroughs, FDA communications, research collaborations, and manufacturing updates. All materials are sourced directly from official company channels to ensure accuracy and compliance.
Bookmark this page for streamlined access to NKTR's latest developments in polymer conjugate chemistry and immunomodulation research. Check regularly for updates that could inform your understanding of the company's scientific trajectory and market position.
Nektar Therapeutics has announced a new strategic plan focusing on key pipeline programs NKTR-358 and NKTR-255, along with a cost restructuring plan. This restructuring will extend the company's cash runway into the first half of 2025, with an expected cash balance of $440-$450 million by year-end. The company will reduce its workforce by approximately 70% to ensure the funding of essential R&D programs without needing to raise external capital for at least three years. Executive changes include the stepping down of Chief Medical Officer Dimitry Nuyten and Chief Commercial Officer John Northcott.
Nektar Therapeutics (Nasdaq: NKTR) unveiled promising preclinical data for NKTR-255, an IL-15 receptor agonist, at the April 2022 Tandem Meetings. Collaborators from New York Medical College showcased how NKTR-255 enhances the efficacy of CAR-T therapies in various cancer models. Key findings included significant proliferation of NK cells and improved anti-tumor activity against Ewing sarcoma and Burkitt lymphoma. Live streaming of presentations occurred on April 23, 2022, emphasizing NKTR-255's potential in boosting immune responses against cancer.
Nektar Therapeutics (NASDAQ:NKTR) will host a conference call for analysts and investors on April 25, 2022, at 2:00 p.m. PST. The call aims to outline a new strategic plan and provide updates on the company's research and development pipeline. Interested parties can access the live audio-only webcast via the Nektar website, where a replay will also be available until May 27, 2022. For participation, dial (877) 881-2183 (U.S.) or (970) 315-0453 (international) with Conference ID: 5888057.
Nektar Therapeutics (NKTR) and Bristol Myers Squibb (BMY) announced the discontinuation of the global clinical development program for bempegaldesleukin in combination with Opdivo after late-stage studies failed to show clinical benefit in renal cell carcinoma and bladder cancer. In the Phase 3 PIVOT-09 study, bempegaldesleukin did not meet the criteria for statistical significance compared to the TKI control arm. The separate Phase 2 PIVOT-10 study also lacked sufficient efficacy. All related studies will be terminated, allowing patients to pursue standard treatment options.
Nektar Therapeutics (NASDAQ:NKTR) is hosting a conference call for analysts and investors on March 14, 2022, at 5:00 a.m. PST. This follows an update from Bristol-Myers Squibb and Nektar regarding the pivotal Phase 3 PIVOT IO-001 study focused on unresectable or metastatic melanoma. The call will be accessible via Nektar's investor relations website and will be available for replay until April 15, 2022.
Bristol Myers Squibb (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) reported disappointing results from the Phase 3 PIVOT IO-001 study evaluating bempegaldesleukin plus Opdivo versus Opdivo alone in metastatic melanoma. The independent Data Monitoring Committee found no significant benefits in progression-free survival (PFS) or objective response rate (ORR). Consequently, the companies decided to unblind the trial and halt enrollment for the related PIVOT-12 study. The focus will now shift to ongoing studies in renal cell carcinoma and bladder cancer.
Nektar Therapeutics (NKTR) reported its financial results for Q4 and full year 2021, noting cash reserves of approximately $0.8 billion, down from $1.2 billion in 2020. Q4 revenue increased to $25.0 million from $23.5 million year-over-year. However, total annual revenue fell to $101.9 million from $152.9 million, largely due to a $50 million milestone recognized in 2020. The company faced a net loss of $145.6 million in Q4, up from $117.2 million in 2020. Key advances were made in clinical trials, including those for NKTR-358 and NKTR-255, with upcoming topline results expected in H1 2022.
Nektar Therapeutics (NKTR) will release its financial results for Q4 and the year ended December 31, 2021, on February 28, 2022, after U.S. market close. CEO Howard Robin will lead a conference call at 5:00 p.m. ET to discuss the results. Investors can access the live audio webcast through Nektar's website, with replays available until March 28, 2022. The company focuses on R&D in oncology, immunology, and virology, with a pipeline of investigational drugs and partnered medicines.
Nektar Therapeutics (Nasdaq: NKTR) CEO Howard Robin will present at the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 11, 2022, at 3:00 p.m. ET. The event will be accessible via a webcast linked on Nektar's Investor Events Calendar and will remain available for replay until February 11, 2022. Nektar is a biopharmaceutical company based in San Francisco, focusing on R&D in oncology, immunology, and virology.
Nektar Therapeutics (NASDAQ: NKTR) announced promising preliminary results from a Phase 1b proof-of-concept study of NKTR-358, a novel T regulatory cell stimulator, in patients with moderate-to-severe atopic dermatitis. The study showed a dose-dependent reduction in EASI scores, with a 70% maximum reduction at the 24 ug/kg dose after 12 weeks. Sustained disease control was observed for at least 6 months post-treatment. The results suggest NKTR-358's potential to differentiate from current treatments, supporting plans for a Phase 2 study by Eli Lilly.
FAQ
What is the current stock price of Nektar Therapeutics (NKTR)?
What is the market cap of Nektar Therapeutics (NKTR)?
